| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5899940 | Diabetes Research and Clinical Practice | 2013 | 10 Pages |
Abstract
Preliminary data suggest GLP-1 RAs could benefit type 2 diabetes patients at risk for CV comorbidities. Additional studies are needed to confirm the extraglycemic and extrapancreatic effects and determine whether outcomes will translate into beneficial effects for patient care.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Susan Herzlinger, Edward S. Horton,